662 Phase I/II study of ipilimumab plus nivolumab combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma by Rohit Jain, Yuanquan Yang, Amir Mortazavi, Jingsong Zhang, Jasreman Dhillon, Youngchul Kim, Wenyi Fan, Guru P Sonpavde, Juskaran Chadha, Monica Chatwal, Sarah Raymond, Erika Saunders, Trey Poehlman